Russia to Expand Digital Prescription Use in September 2026
Russia will introduce changes governing purchases of prescription medicines from September 2026 as digital prescriptions take a larger role. Pharmacies, patients and pharmaceutical retailers will need to prepare their systems and procedures, although the available source does not specify the detailed requirements.
Prescription medicine purchases set to change
Russia is preparing to expand the use of digital prescriptions as part of changes affecting purchases of prescription medicines from September 2026. OSN Media describes the shift as the start of a major technological overhaul of the country’s pharmaceutical market and says paper prescriptions are moving into the past.
The available source does not identify the regulation governing the change or provide a detailed implementation timetable beyond September and autumn 2026. It also does not specify whether paper documents will disappear entirely, remain available in exceptional cases or operate alongside electronic prescriptions during a transition period.
Those details will determine the practical effect on patients and pharmacies. A digital prescription system requires the prescription issued by a medical professional to be available when a pharmacy processes the purchase. Pharmacies will therefore need procedures capable of handling the new format without disrupting access to medicines that cannot be sold without a prescription.
Pharmacies face an operational test
For pharmaceutical retailers, the September change is primarily an information-technology and compliance issue. Pharmacy systems must be ready to work with the prescription format required under the new rules, while employees need clear instructions for checking prescriptions and completing sales. The source provides no figures for expected investment, participating pharmacies or prescription volumes.
Large pharmacy chains may be able to adapt shared software and internal procedures across their networks. Independent outlets could face a different operational burden because each business must ensure that its equipment, connectivity and staff processes are ready by the effective date. The available material does not indicate whether authorities or technology providers will offer financial or technical support.
The transition will also test system reliability. If prescription information cannot be retrieved or verified at the point of sale, pharmacies will need a defined procedure for serving the patient. No fallback mechanism, outage policy or exception for locations with limited connectivity is described in the source material.
Patients need clarity before September
For patients, the central question is how the new procedure changes the purchase itself. Digital prescriptions could reduce dependence on a physical document, but the source does not explain what identification will be required, whether patients will receive a code or notification, or how representatives purchasing medicines for another person will be handled.
Clear public guidance will be important before the September launch. Patients need to know whether existing paper prescriptions remain valid, which pharmacies can process the digital format and what to do when electronic records are unavailable. Pharmacies and medicine suppliers will also be watching whether the change affects dispensing times or demand patterns.
The reform concerns pharmaceutical retail infrastructure rather than a reported change in medicine production, prices or foreign trade. No figures on imports, domestic output, sales or medicine costs are included in the source. Its immediate market significance lies in the readiness of prescription and pharmacy systems when the new procedures begin in autumn 2026.